LIXTE Biotechnology Reports Transformational Year with Clinical Progress and Strategic Expansion

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) has filed its Annual Report on Form 10-K for the year ended December 31, 2025, detailing a year of substantial progress in clinical development and strategic growth initiatives. The company advanced the development of its lead compound LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, which has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. This progress is part of LIXTE's pioneering work in the new field of cancer biology known as activation lethality, which represents a novel treatment paradigm. The company's comprehensive patent portfolio protects this innovative approach, with proof-of-concept clinical trials currently underway for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.

During the reported period, LIXTE expanded its clinical trials by adding new sites and increasing patient enrollment, accelerating the evaluation of LB-100's potential to enhance existing cancer therapies. The company completed the acquisition of Liora Technologies Europe Ltd., a strategic move that enhances its cancer treatment platform. Through this wholly owned subsidiary, LIXTE is developing electronically controlled proton therapy systems, with its proprietary LiGHT System believed to offer significant advantages over current proton therapy technologies for treating various tumors. This acquisition strengthens LIXTE's position in the oncology space by combining pharmaceutical and medical technology approaches.

Financially, LIXTE raised more than $11 million during the year, significantly strengthening its balance sheet and providing resources to support continued research and development activities. This capital infusion positions the company for sustained growth and innovation in the competitive oncology sector. The company's focus remains on developing new targets for cancer drug development and commercializing effective cancer therapies that could improve patient outcomes. Based on published preclinical data, LB-100 has shown potential to significantly enhance both chemotherapies and immunotherapies, offering hope for improved treatment options for cancer patients.

LIXTE's transformational year reflects its commitment to advancing novel cancer treatments through both pharmaceutical and technological approaches. The company's progress with LB-100 development, strategic expansion through the Liora acquisition, and strengthened financial foundation demonstrate its positioning for continued innovation in oncology. Additional information about the company's research and development activities can be found at https://www.lixte.com. The latest updates and news relating to LIXTE are available through various financial communication channels, including specialized platforms that distribute company information to the investment community and broader public audiences.